In February 2011, GSK announced its intention to divest non-core Consumer Healthcare over-the-counter (OTC) products predominantly in the United States and Europe with aggregate sales of approximately £500 million.
More here:
GlaxoSmithKline provides further update on divestment of non-core OTC brands